Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ORMP.TA
- Price
- 8.44
- Stock movement up
- +0.08 (1.15%)
- Company name
- Oramed Pharmaceuticals Inc
- Exchange
- (TA ,
- Currency
- ILA )
- Sector
- Healthcare >Biotechnology
- Market cap
- 287.47M
- Ent value
- 279.77M
- Price/Sales
- 143.73
- Price/Book
- 1.87
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 8307.93%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-11-12
DIVIDENDS
ORMP.TA does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 143.73 |
| Price to Book | 1.87 |
| EV to Sales | 139.88 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 39.85M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | - |
| Gross profit (TTM) | - |
| Operating income (TTM) | - |
| Net income (TTM) | - |
| EPS (TTM) | - |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 15.80M |
| Net receivables | 0.00 |
| Total current assets | 99.03M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 3.48M |
| Total assets | 161.68M |
| Accounts payable | 715.00K |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 3.69M |
| Total liabilities | 8.10M |
| Shareholder's equity | 153.58M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | - |
| Capital expenditures (TTM) | - |
| Free cash flow (TTM) | - |
| Dividends paid (TTM) | - |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 7.13 |
| Daily high | 7.37 |
| Daily low | 7.10 |
| Daily Volume | 33K |
| All-time high | 3365.00 |
| 1y analyst estimate | - |
| Beta | 1.19 |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| ORMP.TA | S&P500 | |
| Current price drop from All-time high | -99.75% | -1.80% |
| Highest price drop | -99.79% | -19.00% |
| Date of highest drop | 6 Nov 2025 | 8 Apr 2025 |
| Avg drop from high | -90.10% | -2.73% |
| Avg time to new high | - | 6 days |
| Max time to new high | 273 days | 89 days |
COMPANY DETAILS
Marketcap
287.47M
Marketcap category
Small-cap
Description
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Country
Israel
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT ADVANCING ORMD-0801 THROUGH CLINICAL STUDIES Trial will focus on key patient subpopulations that have responded to ORMD-0801 following analys...
November 24, 2025
Investors appear disappointed with Oramed Pharmaceuticals Inc.'s ( NASDAQ:ORMP ) recent earnings, despite the decent...
November 21, 2025
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection, today announced its unaudite...
November 17, 2025
The Board of Directors of Oramed Pharmaceuticals Inc. (the "Company") announced today that it has unanimously adopted a Rights Agreement, dated November 17, 2025 (the "Rights Plan"), by and between th...
November 17, 2025
NEW YORK (AP) — Oramed Pharmaceuticals Inc. ORMP) on Thursday reported net income of $48.4 million in its third quarter. The New York-based company said it had profit of $1.13 per share.
November 13, 2025
The truth is that if you invest for long enough, you're going to end up with some losing stocks. But the long term...
October 28, 2025
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed" or the "Company" or "we"), a clinical-stage pharmaceutical company, today issued a Letter to Shareholders from its President and Chief...
October 23, 2025
PALO ALTO, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and co...
October 1, 2025
NEW YORK (AP) — Oramed Pharmaceuticals Inc. ORMP) on Thursday reported net income of $13.3 million in its second quarter. On a per-share basis, the New York-based company said it had profit of 31 cent...
August 14, 2025
By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Company maintains substantial liquidity Oramed Pharmaceuticals (NASDAQ:ORMP) had cash of $74.5 million at the end of March 2025, up from $54....
July 28, 2025
Next page